The May edition of our People Pathways newsletter is available to read here!

Featuring:

✅ One Nucleus upcoming courses

✅ Training Highlights

Earlier this month, the House of Lords passed the Precision Breeding Act which has opened up a new world of opportunity for researchers and food biotech companies at Norwich Research Park.

The Act allows for the gene editing of plants and crops in England, something Tropic, a food biotech company that has been based at Norwich Research Park for several years, is pioneering with crops grown in tropical regions of the world such as bananas and rice as well as closer to home with sugar beet.

• Grant from the Gates Foundation to investigate efficient targeted DNA insertion
• Advance use of proprietary platform for next generation gene therapy applications

• Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactions
• Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions

Amsbio has expanded its range of high-quality antibodies supporting standardization and Quality Assurance in the fast-growing stem cell research and therapeutic field. These optimized antibodies ensure reliable, accurate results in applications including flow cytometry, immunocytochemistry, Western blot, and ELISA.

• Studies presented at leading ophthalmology and gene therapy conferences demonstrate therapeutic potential in geographic atrophy and wet AMD, leading causes of legal blindness
• This single-administration gene therapy approach could replace frequent eye injections for geographic atrophy and wet AMD patients
• The lead candidate IKAR-001 (previously known as IKC159V) will proceed to a geographic atrophy clinical trial supported by studies showing preservation of cells critical for vision

Sandwich, UK - 28 May 2025: Discovery Park has launched applications for its immersive business growth programme, ‘Discovery Spark’, seeking early-stage companies in cardiovascular and cardiometabolic health.

Partnered with health-specialist venture capital firm Zinc, the initiative offers expert-led business skills sessions and the opportunity to secure £250k Zinc investment.

Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster.

MDC’s Chemical Protein Stability Assay (CPSA) is a distinctive technology used to assess target engagement. It can be applied at every step of the drug discovery process to support drug development, screening, and optimisation.

Creative Biolabs is dedicated to helping researchers overcome gene therapy delivery research challenges with its wide technical support and services.